Frontiers in cancer immunology
Activation of the innate immune system represents a promising route for treating cancer; however, it is critical that cells of the immune system selectively target cancer cells and not healthy cells. Come hear about the latest advances in this field and other promising strategies in cancer immunology.
Hye-Jung Kim, Ph.D. is a Senior Scientist at the Dana-Farber Cancer Institute and an Instructor in the Department of Microbiology & Immunobiology at Harvard Medical School. She has published over 20 manuscripts including papers in Nature, Nature Immunology, and PNAS.